TAVHY yields 1.13% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 5
Combined, TAVHY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TAVHY + JNJ for your $10,000?
TAV Havalimanlari Holding A.S., together with its subsidiaries, constructs terminal buildings, and manages and operates terminals or airports in Turkey, Kazakhstan, Georgia, Macedonia, Latvia, Tunisia, Saudi Arabia, Oman, Spain, and internationally. It operates through Terminal Operations, Catering Operations, Duty Free Operations, Ground Handling and Bus Operations, and Other segments. The Terminal Operations segment operates terminal buildings, car parks, and general aviation terminals. This segment also engages in the ground handling operations, as well as operation of parking-apron-taxi ways. The Catering Operations segment manages food and beverage operations of the terminal for passengers and the terminal personnel. The Duty Free Operations segment sells duty free goods for the international arriving and departing passengers. The Ground Handling and Bus Operations segment offers traffic, ramp, flight operation, cargo, and various other ground handling services for domestic and international flights; and operates buses. The Other segment provides lounge, IT, security and education, and airline taxi services. It also provides software and system services. The company was formerly known as Tepe Akfen Vie Yatirim Yapim ve Isletme A.S. and changed its name to TAV Havalimanlari Holding A.S. in August 2006. TAV Havalimanlari Holding A.S. was founded in 1997 and is headquartered in Istanbul, Turkey.
Full TAVHY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.